A phase I/IIa clinical trial for hypophotase treatment has started in collaboration with Shimane University. This First in Human trial is funded by AMED (Japan Agency for Medical Research and Development) and will use PuREC’s REC-01 cells. The aim is to evaluate the safety and efficacy of a new treatment using purified mesenchymal stem cells.
Trial period: July 2021 – September 2022
Find more information in Japanese: https://www.amed.go.jp/news/release_20210715-03.html